McKechnie Duncan 4

What Happened

• McKechnie Duncan, EVP & Chief Commercial Officer of Vertex Pharmaceuticals (VRTX), received a restricted stock unit (RSU) award of 4,962 shares on 2026-02-17 (code A — award/grant, acquisition at $0.00).
• Simultaneously, 1,148 shares were surrendered/withheld to cover tax obligations (code F — tax withholding) at a per-share value of $483.75, totaling $555,345 (disposed).

Key Details

• Transaction date: February 17, 2026.
• Award: 4,962 RSUs granted, acquisition price reported as $0.00.
• Tax withholding: 1,148 shares disposed at $483.75 each = $555,345.
• Approx. 23.1% of the awarded shares were withheld for taxes (1,148 / 4,962).
• Footnote: The RSU award vests in installments beginning February 20, 2027 (F1).
• Shares owned after the transaction are not specified in the provided Form 4 excerpt.
• Filing: Reported on 2026-02-19 (filed timely within the usual Form 4 window).

Context

• This filing reflects a standard RSU grant with routine tax-withholding rather than an open-market purchase or strategic sale. Tax withholding (code F) is common when equity awards vest or are issued; it does not necessarily signal a view on the company’s stock.
• Vesting is deferred (starts 2/20/2027), so the awarded shares are not immediately tradable unless future filings indicate otherwise.